Individualized Survival and Treatment Response Predictions in Breast Cancer Patients: Involvements of Phospho-EGFR and Phospho-Her2/Neu Proteins
Lan Guo*, 1, Jame Abraham2, Daniel C. Flynn3, Vincent Castranova4, Xianglin Shi4 , Yong Qian*, 4
1 MBR Cancer Center/Department of Community Medicine, School of Medicine, West Virginia University, Morgantown, WV 26506-9300, USA
2 Department of Medicine and Division of Hematology/Oncology, West Virginia University, WV 26506-9300, USA
3 MBR Cancer Center/Department of Microbiology, Immunology, and Cell Biology, School of Medicine, West Virginia University, Morgantown, WV 26506-9300, USA
4 The Pathology and Physiology Research Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, WV 26505, USA
Our robust prediction system for individual breast cancer patients combines three well-known machinelearning classifiers to provide stable and accurate clinical outcome prediction (N=269). The average performance of the selected classifiers is used as the evaluation criterion in breast cancer outcome predictions. A profile (incorporating histology, lymph node status, tumor grade, tumor stage, ER, PR, Her2/neu, patient’s age and smoking status) generated over 95% accuracy in individualized disease-free survival and treatment response predictions. Furthermore, our analysis demonstrated that the measurement of phospho-EGFR and phospho-Her2/neu is more powerful in breast cancer survival prediction than that of total EGFR and total Her2/neu (p < 0.05). The incorporation of hormone receptor status, Her2/neu, patient’s age and smoking status into the traditional pathologic markers creates a powerful standard to perform individualized survival and treatment outcome predictions for breast cancer patients
Keywords: Prognosis, antibody, breast cancer, EGFR, Her2/neu, molecular pathogenesis..
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which
permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
* Address correspondence to these authors at the MBR Cancer Cen-
ter/Department of Community Medicine, School of Medicine, West Virginia University, Morgantown, WV 26506-9300, USA; Fax: (304) 293-4667; Tel: (304) 293-6455; E-mail: